Cellshine has signed a Memorandum of Understanding (MOU) with Kukje Pharmaceutical for the commercialization of a fluorescent contrast agent designed for conjunctival goblet cell staining.
Under the agreement, the two companies will jointly pursue the full commercialization process — from formulation development and clinical trials to regulatory approval and mass production. Kukje Pharma will lead formulation design, manufacturing process development, and regulatory preparation, while Cellshine will provide technical support for preclinical and clinical studies required for approval.
This partnership marks a significant step in expanding Cellshine’s dry eye diagnostic platform, GobLens, from a standalone imaging device to an integrated diagnostic solution that includes a dedicated contrast agent.